JP2024515100A - 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ - Google Patents

特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ Download PDF

Info

Publication number
JP2024515100A
JP2024515100A JP2023564130A JP2023564130A JP2024515100A JP 2024515100 A JP2024515100 A JP 2024515100A JP 2023564130 A JP2023564130 A JP 2023564130A JP 2023564130 A JP2023564130 A JP 2023564130A JP 2024515100 A JP2024515100 A JP 2024515100A
Authority
JP
Japan
Prior art keywords
ctla4
combination
itf3756
treatment
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515100A5 (https=
Inventor
フォサーティ ジャンルカ
レオーニ フラヴィオ
サムエレ ポッツィ ピエトロ
ガルビアーティ エリザベッタ
ステインクーラー クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of JP2024515100A publication Critical patent/JP2024515100A/ja
Publication of JP2024515100A5 publication Critical patent/JP2024515100A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023564130A 2021-04-20 2022-04-19 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ Pending JP2024515100A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102021000009926 2021-04-20
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (2)

Publication Number Publication Date
JP2024515100A true JP2024515100A (ja) 2024-04-04
JP2024515100A5 JP2024515100A5 (https=) 2025-03-14

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564130A Pending JP2024515100A (ja) 2021-04-20 2022-04-19 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ

Country Status (17)

Country Link
US (1) US20240207228A1 (https=)
EP (1) EP4326259A1 (https=)
JP (1) JP2024515100A (https=)
KR (1) KR20230172001A (https=)
CN (1) CN117177745A (https=)
AR (1) AR125356A1 (https=)
AU (1) AU2022262199A1 (https=)
BR (1) BR112023021125A2 (https=)
CA (1) CA3213275A1 (https=)
CL (1) CL2023002894A1 (https=)
CO (1) CO2023013780A2 (https=)
IL (1) IL307649A (https=)
IT (1) IT202100009926A1 (https=)
MX (1) MX2023012030A (https=)
PE (1) PE20242078A1 (https=)
TW (1) TW202308609A (https=)
WO (1) WO2022223543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501205A (ja) * 2016-01-11 2019-01-17 ターンストーン リミテッド パートナーシップ 腫瘍崩壊性ウイルス及びチェックポイント阻害剤の併用療法
JP2020516671A (ja) * 2017-04-14 2020-06-11 イタルファルマコ ソシエタ ペル アチオニＩｔａｌｆａｒｍａｃｏ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 選択的ｈｄａｃ６阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501205A (ja) * 2016-01-11 2019-01-17 ターンストーン リミテッド パートナーシップ 腫瘍崩壊性ウイルス及びチェックポイント阻害剤の併用療法
JP2020516671A (ja) * 2017-04-14 2020-06-11 イタルファルマコ ソシエタ ペル アチオニＩｔａｌｆａｒｍａｃｏ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 選択的ｈｄａｃ６阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
""P630 Induction of antitumor immuneresponse by selective HDAC6 inhibition"", 34TH ANNUAL MEETING &PRE-CONFERENCE PROGRAMS OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC 2019):, vol. Vol.7(S1), JPN6026008466, 2019, pages 66 - 67, ISSN: 0005808024 *
CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 6, no. 6, JPN6026008468, 2005, pages 582 - 591, ISSN: 0005808025 *

Also Published As

Publication number Publication date
BR112023021125A2 (pt) 2023-12-12
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
WO2022223543A1 (en) 2022-10-27
AU2022262199A1 (en) 2023-09-21
US20240207228A1 (en) 2024-06-27
CL2023002894A1 (es) 2024-03-15
AR125356A1 (es) 2023-07-12
TW202308609A (zh) 2023-03-01
KR20230172001A (ko) 2023-12-21
IT202100009926A1 (it) 2022-10-20
IL307649A (en) 2023-12-01
CO2023013780A2 (es) 2023-11-10
CN117177745A (zh) 2023-12-05
MX2023012030A (es) 2023-10-24
CA3213275A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US11744822B2 (en) Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
AU2014253978B2 (en) Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
EP4257609A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
KR20230098279A (ko) Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
JP2024515100A (ja) 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
EA050310B1 (ru) Комбинация, содержащая специфический ингибитор hdac6 и по меньшей мере одно антитело к ctla4
CA3019391C (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK40125832A (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
JP2025159734A (ja) 抗線維化作用を有する低分子化合物と免疫チェックポイント制御剤との併用によるがん療法
JP2024527978A (ja) 腫瘍の予防または処置のための医薬組成物およびその使用
JP2023516155A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
HK40126790A (zh) 在wnt通路肿瘤阻抑基因中具有突变的癌症的治疗
CA3143210A1 (en) Hsp90-binding conjugates and combination therapies thereof
EA046076B1 (ru) Ингибиторы csf1r для применения в лечении рака
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303